CN1041520C - 喹啉或喹唑啉衍生物,它们的制法和用途 - Google Patents

喹啉或喹唑啉衍生物,它们的制法和用途 Download PDF

Info

Publication number
CN1041520C
CN1041520C CN94101137A CN94101137A CN1041520C CN 1041520 C CN1041520 C CN 1041520C CN 94101137 A CN94101137 A CN 94101137A CN 94101137 A CN94101137 A CN 94101137A CN 1041520 C CN1041520 C CN 1041520C
Authority
CN
China
Prior art keywords
compound
ring
group
salt
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94101137A
Other languages
English (en)
Chinese (zh)
Other versions
CN1105363A (zh
Inventor
左右田隆
牧野治彦
马场厚生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN1105363A publication Critical patent/CN1105363A/zh
Application granted granted Critical
Publication of CN1041520C publication Critical patent/CN1041520C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN94101137A 1993-01-28 1994-01-28 喹啉或喹唑啉衍生物,它们的制法和用途 Expired - Fee Related CN1041520C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP012628/93 1993-01-28
JP1262893 1993-01-28
JP20612893 1993-08-20
JP206128/93 1993-08-20

Publications (2)

Publication Number Publication Date
CN1105363A CN1105363A (zh) 1995-07-19
CN1041520C true CN1041520C (zh) 1999-01-06

Family

ID=26348258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94101137A Expired - Fee Related CN1041520C (zh) 1993-01-28 1994-01-28 喹啉或喹唑啉衍生物,它们的制法和用途

Country Status (15)

Country Link
US (3) US5436247A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0608870B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100224135B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1041520C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE205199T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU673213B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2114300C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69428142T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI940414L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU217907B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO940245D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ250761A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2132330C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG50546A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW256832B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW232013B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
ATE188377T1 (de) * 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
US5650410A (en) * 1994-03-08 1997-07-22 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing quinoline or quinazoline derivatives and derivatives therefor
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them
AU2683195A (en) * 1994-06-24 1996-01-19 Takeda Chemical Industries Ltd. Processes for production of quinoline or quinazoline derivatives and intermediates therefor
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
EP0830133A1 (en) * 1995-04-28 1998-03-25 Takeda Chemical Industries, Ltd. Therapeutic composition for arthritis
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BR9809172A (pt) * 1997-05-28 2000-08-01 Rhone Poulenc Rorer Pharma Composto, composição farmacêutica, e, processos de inibir a atividade da tirosina cinase pdgf, a atividade da tirosina cinase lck, a proliferação celular, diferenciação ou liberação de mediador em um paciente, para tratar uma patologia ligada a um distúrbio hiperproliferativo, para tratar restenose e para tratar a inflamação em um paciente
DE19728835C1 (de) * 1997-07-05 1998-09-10 Ruetgers Vft Ag Verfahren zur Reinigung von Chinaldin
SI1249450T1 (sl) * 2000-01-17 2008-04-30 Teijin Pharma Ltd Derivati benzimidola kot inhibitorji humane kimaze
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
RU2183116C1 (ru) * 2001-07-10 2002-06-10 Жаров Олег Владимирович Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
ATE394398T1 (de) * 2002-07-15 2008-05-15 Scinopharm Taiwan Ltd Verfahren zur herstellung von imidazo(1,2- a)pyridin-3-acetamiden
AU2003277572A1 (en) * 2002-11-06 2004-06-07 Nissan Chemical Industries, Ltd. Process for producing quinolinecarbaldehyde
EP1618094B1 (en) * 2003-04-30 2007-09-05 The Institutes for Pharmaceutical Discovery, LLC Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US7937406B2 (en) * 2003-09-11 2011-05-03 Oracle America, Inc. Mechanism for automatically establishing a resource grid
KR100876470B1 (ko) * 2004-11-01 2008-12-31 에프. 호프만-라 로슈 아게 Ｇａｂａ-ｂ 수용체의 알로스테릭 증강자로서 퀴놀린
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
JP2009530032A (ja) * 2006-03-21 2009-08-27 アルザ・コーポレーシヨン 薬剤電気輸送のための水和可能な高分子量エステルマトリックス
AR077267A1 (es) 2009-06-25 2011-08-17 Amgen Inc Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
US8765768B2 (en) 2010-11-17 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
JP6258937B2 (ja) * 2012-08-24 2018-01-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規二環式ピリジン誘導体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563455A (en) * 1983-03-22 1986-01-07 Fujisawa Pharmaceutical Co., Ltd. Antiulcer fused imidazole compounds
US5151421A (en) * 1988-11-29 1992-09-29 Janssen Pharmaceutica N.V. (1h-azol-1-ylmethyl) substituted quinoxaline derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
US5084462A (en) * 1988-04-26 1992-01-28 The Du Pont Merck Pharmaceutical Company 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
TW232013B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
AU2683195A (en) * 1994-06-24 1996-01-19 Takeda Chemical Industries Ltd. Processes for production of quinoline or quinazoline derivatives and intermediates therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563455A (en) * 1983-03-22 1986-01-07 Fujisawa Pharmaceutical Co., Ltd. Antiulcer fused imidazole compounds
US5151421A (en) * 1988-11-29 1992-09-29 Janssen Pharmaceutica N.V. (1h-azol-1-ylmethyl) substituted quinoxaline derivatives

Also Published As

Publication number Publication date
KR100224135B1 (ko) 1999-10-15
FI940414A7 (fi) 1994-07-29
NO940245D0 (no) 1994-01-24
AU673213B2 (en) 1996-10-31
DE69428142D1 (de) 2001-10-11
US5436247A (en) 1995-07-25
US5932592A (en) 1999-08-03
NO940245L (no) 1994-07-29
NO306992B1 (no) 2000-01-24
US5770602A (en) 1998-06-23
FI940414A0 (fi) 1994-01-27
DE69428142T2 (de) 2002-07-04
AU5474294A (en) 1994-08-04
KR940018381A (ko) 1994-08-16
CN1105363A (zh) 1995-07-19
EP0608870B1 (en) 2001-09-05
HUT70194A (en) 1995-09-28
ATE205199T1 (de) 2001-09-15
TW256832B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-09-11
CA2114300A1 (en) 1994-07-29
RU2132330C1 (ru) 1999-06-27
HU9400250D0 (en) 1994-05-30
SG50546A1 (en) 1998-07-20
FI940414L (fi) 1994-07-29
EP0608870A1 (en) 1994-08-03
NZ250761A (en) 1995-03-28
CA2114300C (en) 2000-10-17
HU217907B (hu) 2000-05-28

Similar Documents

Publication Publication Date Title
CN1041520C (zh) 喹啉或喹唑啉衍生物,它们的制法和用途
CN1022566C (zh) 制备新的取代的1-哌啶亚烷基-吡啶并嘧啶酮或噻唑并嘧啶酮的方法
TWI813611B (zh) 作為parp14抑制劑之喹唑啉酮
JP5853035B2 (ja) β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体
CN1095841C (zh) 化合物
CN1281590C (zh) 具有抑制血管生成活性的六员氨基酰胺类衍生物
CN1129216A (zh) 三环取代异羟肟酸衍生物
CN1186492A (zh) 咪唑并[1,2－α]吡啶衍生物
JP6787998B2 (ja) 置換３−（３−アニリノ−１−シクロヘキシル−１ｈ−ベンズイミダゾール−５−イル）プロパン酸誘導体を調製する方法
SG185652A1 (en) 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
CN1429200A (zh) 邻氨基苯甲酸酰胺及其作为药物的应用
RU2649976C2 (ru) Способ получения бензоксазепиновых соединений
CN1278263A (zh) 2,3－二芳基－吡唑并[1,5－b]哒嗪衍生物,其制备方法和用作环氧酶2(cox－2)抑制剂的用途
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1046505C (zh) 1－苄基－3－羟甲基－吲唑与脂族2－羟基酸的醚的制法
CN1094406A (zh) 用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮
TW200300088A (en) Piperazine derivatives having ssti antagonistic activity
CN1009826B (zh) 制备喹啉基化合物的方法
CN86103227A (zh) 制备2-吡咯烷酮衍生物的方法
CN87100686A (zh) 用作心血管剂的3-烷氧基-2-氨基丙胺类化合物
CN1194982A (zh) 磺酰氨取代的苯并二氢吡喃、其制备方法、它们作为药物或诊断剂的用途和含有它们的药物
EP3424927A1 (en) Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid
CN1198735A (zh) 苯磺酰胺衍生物以及它们的制备和在医领域中的应用
CN1083066A (zh) 噻吩并噻嗪衍生物和它们的制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee